Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | MHC Class I Antigens In Malignant Cells - Immune Escape And Response To Immunotherapy

MHC Class I Antigens In Malignant Cells

Immune Escape And Response To Immunotherapy

Aptsiauri, Natalia, Garcia-Lora, Angel Miguel, Cabrera, Teresa

2013, VIII, 51 p. 17 illus., 14 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$39.95

(net) price for USA

ISBN 978-1-4614-6543-0

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$49.95

(net) price for USA

ISBN 978-1-4614-6542-3

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Discusses molecular mechanisms of total or partial loss of the MHC class I antigens in cancer cells
  • Explains the role of MHC class I defects in cancer progression
  • Shows the correlation of MHC class I altered phenotypes with resistance to Immunotherapy ​
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​  

Content Level » Research

Keywords » Immunotherapy - MHC class I - cancer - immune escape - metastasis - tumor rejection

Related subjects » Cancer Research - Immunology - Molecular Medicine

Table of contents / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.